Ryanne Ashley Brown, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Stanford Health Care · Associated Pathology Medical Group Inc · Diagnostic Pathology Services of the Central Coast
Looking this up.
Hospitals listed: Lompoc Valley Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Brown’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A126737 · Current
Licensed to practise in California · since 2013 · expires 2027-08-31 · Baylor College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lompoc Valley Medical CenterLompoc, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 2 of 5 · 45% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Lompoc Valley Medical Center
Behind the star rating — Deaths: 0 better, 3 the same, 2 worse of 5 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.76 (0.72 to 2.79) · 397 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.01 (0.57 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 10.6 · 53 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.6 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 21.1 · 166 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.4 · 46 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.1 · 470 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,795 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,747 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.06 (0.59 to 5.53) · 334 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 194 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (0.82 to 4.18) · 327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.15 (3.05 to 21.25) · 190 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.54 (1.44 to 9.65) · 172 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.23) · 129 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.5) · 1,468 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.1 · 30 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.608 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.782 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 69 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.8 · 88 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 82.8 · 147 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.6 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.6 to 15.1) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 30 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.8 to 16.9) · 1,023 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 73 cases | No different | Jan 2024 – Dec 2024 |
What patients said (182 patients answered, 14% of those asked)
| Cleanliness | 4 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 66% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 47% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 64% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 46% |
| Staff "always" explained new medications | 63% |
| Nurses "always" explained things so they could understand | 60% |
| Nurses "always" listened carefully | 64% |
| Nurses "always" treated them with courtesy and respect | 75% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 45% |
| Staff "always" explained possible side effects | 31% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$545,441
Medicare paid this office $545,441 for 5,031 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 3,909 | $311,314 | $49 |
| Special stained specimen slides to examine tissue, initial procedure | 828 | $58,010 | $54 |
| Special stained specimen slides to examine tissue, each additional procedure | 598 | $52,074 | $45 |
| Special stained specimen slides to identify organisms including interpretation and report | 285 | $26,532 | $64 |
| Pathology examination of tissue using a microscope, intermediate complexity | 524 | $24,665 | $32 |
See all 19 services
| Pathology examination of tissue using a microscope, intermediate complexity | 3,909 | $311,314 | $49 |
| Special stained specimen slides to examine tissue, initial procedure | 828 | $58,010 | $54 |
| Special stained specimen slides to examine tissue, each additional procedure | 598 | $52,074 | $45 |
| Special stained specimen slides to identify organisms including interpretation and report | 285 | $26,532 | $64 |
| Pathology examination of tissue using a microscope, intermediate complexity | 524 | $24,665 | $32 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 290 | $22,496 | $72 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 181 | $15,397 | $80 |
| Pathology examination of tissue using a microscope, moderately low complexity | 231 | $7,645 | $29 |
| Special stained specimen slides to examine tissue, each additional procedure | 63 | $3,783 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 92 | $3,577 | $31 |
| Special stained specimen slides to examine tissue including interpretation and report | 38 | $3,153 | $64 |
| Special stained specimen slides to identify organisms including interpretation and report | 81 | $2,813 | $24 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 37 | $2,784 | $73 |
| Microscopic genetic analysis of tumor, manual | 28 | $1,756 | $55 |
| Microscopic genetic analysis of tumor, manual | 19 | $1,752 | $37 |
| Antibody evaluation, each additional single antibody stain procedure | 14 | $1,618 | $26 |
| Pathology examination of tissue using a microscope, moderately high complexity | 13 | $1,593 | $72 |
| Antibody evaluation, initial single antibody stain procedure | 14 | $452 | $32 |
| Pathology examination of tissue using a microscope, moderately low complexity | 36 | $376 | $10 |
Who their Medicare patients are
5,031 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 18% · Women 48% · Also on Medicaid 6% · Health risk score 1.05. At or below the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 63% · Coronary heart disease 22% · Cancer 19% · Atrial fibrillation 19% · Chronic kidney disease 18% · Diabetes 17% · Depression 14% · Heart failure 10% · COPD 9% · Stroke 6% · Dementia 4%.
The office billed $2,095,319, Medicare allowed $700,782 and paid $545,441; for 11,314 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 5,031 | 11,314 | 77 | 1.05 | $2,095,319 | $545,441 |
| 2023 | 5,015 | 10,532 | 76 | 1.04 | $1,917,397 | $527,828 |
| 2022 | 4,576 | 10,211 | 76 | 1.01 | $1,606,605 | $488,429 |
| 2021 | 3,614 | 7,774 | 76 | 0.99 | $1,033,570 | $405,652 |
| 2020 | 307 | 798 | 75 | 1.59 | $155,318 | $28,156 |
| 2019 | 448 | 1,118 | 75 | 1.44 | $208,186 | $37,153 |
| 2018 | 147 | 359 | 74 | 1.23 | $66,755 | $12,553 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 21 services
| Pathology examination of tissue using a microscope, intermediate complexity | 3,966 | $303,659 | $51 |
| Special stained specimen slides to examine tissue, initial procedure | 718 | $53,444 | $61 |
| Special stained specimen slides to examine tissue, each additional procedure | 507 | $47,080 | $49 |
| Special stained specimen slides to identify organisms including interpretation and report | 325 | $31,002 | $65 |
| Pathology examination of tissue using a microscope, intermediate complexity | 505 | $24,253 | $33 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 187 | $14,649 | $76 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 161 | $13,774 | $81 |
| Special stained specimen slides to examine tissue including interpretation and report | 79 | $7,042 | $70 |
| Pathology examination of tissue using a microscope, moderately low complexity | 220 | $6,497 | $27 |
| Special stained specimen slides to examine tissue, each additional procedure | 83 | $5,258 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 108 | $4,292 | $32 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 36 | $2,727 | $76 |
| Special stained specimen slides to identify organisms including interpretation and report | 73 | $2,650 | $24 |
| Pathology examination of tissue using a microscope, moderately high complexity | 12 | $1,700 | $74 |
| Microscopic genetic analysis of tumor, manual | 16 | $1,545 | $59 |
| Antibody evaluation, each additional single antibody stain procedure | 14 | $1,507 | $27 |
| Microscopic genetic analysis of tumor, manual | 14 | $1,124 | $39 |
| Detection test by nucleic acid for human papillomavirus (hpv), high-risk types | 16 | $550 | $34 |
| Antibody evaluation, initial single antibody stain procedure | 14 | $466 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 32 | $278 | $9 |
| Pathology examination of tissue using a microscope, limited examination | 11 | $57 | $5 |
2022: 19 services
| Pathology examination of tissue using a microscope, intermediate complexity | 3,588 | $259,130 | $46 |
| Special stained specimen slides to examine tissue, initial procedure | 619 | $48,284 | $63 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 443 | $34,141 | $69 |
| Special stained specimen slides to identify organisms including interpretation and report | 329 | $30,299 | $69 |
| Special stained specimen slides to examine tissue, each additional procedure | 359 | $29,935 | $43 |
| Pathology examination of tissue using a microscope, intermediate complexity | 491 | $24,412 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 174 | $14,192 | $76 |
| Special stained specimen slides to examine tissue including interpretation and report | 93 | $10,197 | $78 |
| Pathology examination of tissue using a microscope, moderately low complexity | 304 | $9,032 | $27 |
| Special stained specimen slides to examine tissue, each additional procedure | 83 | $5,221 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 109 | $4,407 | $32 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 51 | $4,028 | $77 |
| Special stained specimen slides to identify organisms including interpretation and report | 82 | $3,842 | $24 |
| Microscopic genetic analysis of tumor, manual | 13 | $2,341 | $39 |
| Antibody evaluation, each additional single antibody stain procedure | 20 | $2,195 | $27 |
| Antibody evaluation, initial single antibody stain procedure | 20 | $705 | $34 |
| Pathology examination of tissue using a microscope, moderately low complexity | 24 | $254 | $9 |
| Special stained specimen slides to examine tissue including interpretation and report | 12 | $213 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 23 | $99 | $4 |
2021: 16 services
| Pathology examination of tissue using a microscope, intermediate complexity | 2,968 | $221,830 | $49 |
| Special stained specimen slides to examine tissue, initial procedure | 472 | $56,902 | $80 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 401 | $36,818 | $79 |
| Special stained specimen slides to identify organisms including interpretation and report | 215 | $20,649 | $65 |
| Pathology examination of tissue using a microscope, intermediate complexity | 315 | $16,088 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 168 | $13,304 | $35 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 104 | $9,932 | $89 |
| Pathology examination of tissue using a microscope, moderately low complexity | 206 | $7,002 | $31 |
| Special stained specimen slides to examine tissue including interpretation and report | 65 | $6,143 | $79 |
| Special stained specimen slides to examine tissue, each additional procedure | 47 | $3,153 | $27 |
| Special stained specimen slides to examine tissue, initial procedure | 61 | $2,811 | $33 |
| Special stained specimen slides to identify organisms including interpretation and report | 50 | $2,611 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 17 | $1,346 | $79 |
| Detection test by nucleic acid for human papillomavirus (hpv), high-risk types | 11 | $386 | $35 |
| Pathology examination of tissue using a microscope, moderately low complexity | 24 | $220 | $9 |
| Pathology examination of tissue using a microscope, limited examination | 17 | $70 | $4 |
2020: 8 services
| Pathology examination of tissue using a microscope, intermediate complexity | 261 | $13,583 | $36 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 35 | $2,810 | $78 |
| Special stained specimen slides to identify organisms including interpretation and report | 43 | $2,445 | $26 |
| Special stained specimen slides to examine tissue, each additional procedure | 33 | $2,170 | $27 |
| Special stained specimen slides to examine tissue, initial procedure | 53 | $2,135 | $34 |
| Antibody evaluation, each additional single antibody stain procedure | 15 | $1,685 | $28 |
| Microscopic genetic analysis of tumor, manual | 16 | $1,392 | $41 |
| Antibody evaluation, initial single antibody stain procedure | 15 | $521 | $35 |
2019: 8 services
| Pathology examination of tissue using a microscope, intermediate complexity | 395 | $18,757 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 55 | $4,167 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 91 | $3,682 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 35 | $2,541 | $73 |
| Special stained specimen slides to identify organisms including interpretation and report | 48 | $2,370 | $24 |
| Antibody evaluation, each additional single antibody stain procedure | 18 | $1,871 | $27 |
| Antibody evaluation, initial single antibody stain procedure | 18 | $593 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 14 | $128 | $9 |
2018: 4 services
| Pathology examination of tissue using a microscope, intermediate complexity | 127 | $6,540 | $36 |
| Special stained specimen slides to examine tissue, initial procedure | 39 | $1,862 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 19 | $1,521 | $27 |
| Special stained specimen slides to identify organisms including interpretation and report | 15 | $686 | $25 |
Medicaid work
$24,075 in 2024
Medicaid paid $24,075 for 593 billed services this clinician did in 2024, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 593 | $24,075 |
| 2024 | 593 | 1 | 38 | $24,075 |
| 2023 | 980 | 5 | 55 | $42,251 |
| 2022 | 670 | 3 | 50 | $25,043 |
| 2021 | 300 | 2 | 34 | $13,090 |
| 2020 | 52 | 1 | 15 | $2,974 |
| 2019 | 82 | 1 | 26 | $3,156 |
| 2018 | 21 | 1 | 20 | $1,069 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 927 | $39,724 |
| TISSUE EXAM BY PATHOLOGIST | 13 | $1,009 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 13 | $758 |
| TISSUE EXAM BY PATHOLOGIST | 15 | $408 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 12 | $352 |
2022
| TISSUE EXAM BY PATHOLOGIST | 606 | $22,679 |
| TISSUE EXAM BY PATHOLOGIST | 51 | $1,665 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 13 | $699 |
2021
| TISSUE EXAM BY PATHOLOGIST | 288 | $12,821 |
| TISSUE EXAM BY PATHOLOGIST | 12 | $269 |
2020
| TISSUE EXAM BY PATHOLOGIST | 52 | $2,974 |
2019
| TISSUE EXAM BY PATHOLOGIST | 82 | $3,156 |
2018
| TISSUE EXAM BY PATHOLOGIST | 21 | $1,069 |
Money from drug and device companies
$27 in 2023
A payment is not proof that care is biased.
| Roche Diagnostics | Benchmark Special Stains Wash II | $27 | 1 payment
|
See the published payment
| Roche Diagnostics | Meals · 2023-04-26 | Benchmark Special Stains Wash II | $27 |
Professional record
- NPI
- 1780940106
- Licence
- CA A126737California A126737: Current · expires 2027-08-31
- Trained
- Baylor College of Medicine, 2012
- Group
- Stanford Health Care · Associated Pathology Medical Group Inc · Diagnostic Pathology Services of the Central Coast
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZD0900X (207ZD0900X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-04-10
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.